Página principal > Resultados de la búsqueda: Cheung, Leo W.K.
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
9 p, 442.2 KB B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy / Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ; Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ; Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ; Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ; Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ; Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - 10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073  
Registro completo - Creative Commons
2.
13 p, 1.9 MB Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features : integrated analysis of two phase 3 studies / Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Demirkan, Fatih (Dokuz Eylul University) ; Bairey, Osnat (Rabin Medical Center) ; Moreno, Carolina (Institut d'Investigació Biomèdica Sant Pau) ; Simpson, D. (BeiGene) ; Munir, Talha (Department of Haematology. St. James's Hospital) ; Stevens, D.A. (Norton Cancer Institute) ; Dai, S. (Pharmacyclics LLC. an AbbVie Company) ; Cheung, Leo W. K (Pharmacyclics LLC. an AbbVie Company) ; Kwei, Kevin (Pharmacyclics LLC. an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC. an AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego. Moores Cancer Center) ; Tedeschi, A. (ASST Grande Ospedale Metropolitano Niguarda)
Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in BIRC3, NOTCH1, SF3B1, and XPO1 predict poor outcomes with chemoimmunotherapy in chronic lymphocytic leukemia. [...]
2022 - 10.1080/10428194.2021.2020779
Leukemia and Lymphoma, Vol. 63 Núm. 6 (2022) , p. 1375-1386  
Registro completo - Creative Commons
3.
10 p, 631.8 KB Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study / Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ; Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ; Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ; Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ; Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ; Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ; Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Cheung, L.K.
1 Cheung, Leo W. K
1 Cheung, Leo W. K.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos